Echocardiographic prevalence of mitral and/or aortic regurgitation in patients exposed to either fenfluramine-phentermine combination or to dexfenfluramine

American Journal of Cardiology

Volumn 84, Issue 11, 1999, Pages 1335-1338

  Kancherla, Madhu K ^a   Salti, Hani I ^a   Mulderink, Todd A ^a   Parker, Michele ^a   Bonow, Robert O ^a   Mehlman, David J ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANOREXIGENIC AGENT; DEXFENFLURAMINE; FENFLURAMINE; PHENTERMINE;

ADULT; AORTA VALVE REGURGITATION; ARTICLE; CARDIOTOXICITY; COLOR ULTRASOUND FLOWMETRY; CONTROLLED STUDY; ECHOCARDIOGRAPHY; FEMALE; HEART VALVE REGURGITATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MITRAL VALVE REGURGITATION; PREVALENCE; PRIORITY JOURNAL;

ADULT; AGED; AORTIC VALVE; AORTIC VALVE INSUFFICIENCY; APPETITE DEPRESSANTS; BLOOD FLOW VELOCITY; DEXFENFLURAMINE; DRUG COMBINATIONS; ECHOCARDIOGRAPHY, DOPPLER, COLOR; FEMALE; FENFLURAMINE; HUMANS; MALE; MIDDLE AGED; MITRAL VALVE; MITRAL VALVE INSUFFICIENCY; NORTHWESTERN UNITED STATES; OBESITY; PHENTERMINE; PREVALENCE; PULMONARY WEDGE PRESSURE; QUESTIONNAIRES; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES;

EID: 0032747457     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(99)00567-6     Document Type: Article

References (14)

1. Weintraub M., Hasday J.D., Mushlin A.I., Lockwood D.H. A double-blind clinical trial in weight control. Use of fenfluramine and phentermine alone and in combination. Arch Intern Med. 144:1984;1143-1148.
2. Cardiac valvulopathy associated with exposure to fenfluramine or dexfluramine US Department of Health and Human Services Interim public health recommendations . MMWR Morb Mortal Wkly Rep. 46:1997;1061-1066.
3. Connolly H.M., Crary J.L., McGoon M.D., Hensrud D.D., Edwards B.S., Edwards W.D., Schaff H.V. Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med. 337:1997;581-588.
4. Ranganathan N., Lam J.H., Wigle E.D., Silver M.D. Morphology of the human mitral valve II. The valve leaflets. Circulation. 41:1970;459-467.
5. Yock P.G., Popp R.L. Noninvasive estimation of right ventricular systolic pressure by Doppler ultrasound in patients with tricuspid regurgitation. Circulation. 70:1984;657-662.
6. Yoshida K., Yoshikawa J., Shakudo M., Akasaka T., Jyo Y., Takao S., Shiratori K., Koizumi K., Okumachi F., Kato H., Fukaya T. Color Doppler evaluation of valvular regurgitation in normal subjects. Circulation. 78:1988;840-847.
7. Biava G., Delfino M., Lagana B., Urani C., Camera A., Modica M., Del Porto R. Prevalence of valvular regurgitation in structurally normal hearts a color-Doppler study . Coron Artery Dis. 8:1997;559-563.
8. Kurz X., Ermen A. Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med. 337:1997;1772-1773.
9. Rasmussen S., Corya B.C., Glassman R.D. Valvular heart disease associated with fenfluramine-phentermine [letter]. N Engl J Med. 337:1997;1773.
10. Robiolio P.A., Rigolin V.H., Wilson J.S., Harrison J.K., Sanders L.L., Bashore T.M., Feldman J.M. Carcinoid heart disease. Correlation of high serotonin levels with valvular abnormalities detected by cardiac catheterization and echocardiography. Circulation. 92:1995;790-795.
11. Redfield M.M., Nicholson W.J., Edwards W.D., Tajik A.J. Valve disease associated with ergot alkaloid use echocardiographic and pathological correlations . Ann Intern Med. 117:1992;50-52.
12. Khan M.A., Herzog C.A., St. Peter J.V., Hartley G.G., Madlon-Kay R., Dick C.D., Asinger R.W., Vessley J.T. The prevalence of cardiac valvular insufficiency assessed by transthoracic echocardiography in obese patients treated with appetite-suppressant drugs. N Engl J Med. 339:1998;713-718.
13. Jick H., Vasilakis C., Weinrauch L.A., Meier C.R., Jick S.S., Derby L.E. A population-based study of appetite-suppressant drugs and the risk of cardiac-valve regurgitation. N Engl J Med. 339:1998;719-724.
14. Weissman N.J., Tighe J.F., Gottdiener J.S., Gwynne J.T. An assessment of heart-valve abnormalities in obese patients taking dexfenfluramine, sustained-release dexfenfluramine, or placebo. N Engl J Med. 339:1998;725-732.